| Adverse outcomes (n = 4) | Non-adverse outcomes (n = 6) | p | |
|---|---|---|---|
| Maternal characteristics | |||
| Maternal age (years) | 31.0 (29.5-33.5) | 33.5 (30.0-34.8) | 0.668 |
| Primiparity | 2 (50.0) | 5 (83.3) | 0.500 |
| Infertility treatment | 1 (25.0) | 1 (16.7) | 1.00 |
| Body mass index | 21.5 (21.0-23.7) | 19.8 (18.5-21.6) | 0.088 |
| GA at birth (weeks) | 36.0 (35.3-36.3) | 35.5 (34.0-37.0) | 0.912 |
| Cesarean section | 3 (75.0) | 5 (83.3) | 1.00 |
| Fetal/Placental characteristics | |||
| GA at initial thoracocentesis (weeks) | 30.5 (27.8-32.0) | 27.0 (24.5-29.5) | 0.454 |
| Bilateral FPE | 3 (75.0) | 4 (66.7) | 1.00 |
| Large amount of FPE | 3 (75.0) | 4 (66.7) | 1.00 |
| Total cell counts in FPE (/μL) | 871.7 (694.2-3090) | 5100 (1259-13090) | 1.00 |
| Percentage of lymphocytes in FPE (%) | 95.2 (92.2-97.6) | 96.3 (88.6-98.5) | 1.00 |
| Total protein in FPE (g/L) | 18.7 (16.1-21.9) | 22.1 (15.8-24.8) | 0.831 |
| Hydrops | 3 (75.0) | 2 (33.3) | 0.524 |
| Polyhydramnios | 1 (25.0) | 4 (66.7) | 0.524 |
| Histological chorioamnionitis | 1 (25.0) | 1 (16.7) | 1.00 |
| Neonatal characteristics | |||
| Birth weight* (g) | 2415 (2276-2546) | 2854 (2587-2904) | 0.201 |
| Male | 2 (50.0) | 5 (83.3) | 0.500 |
| 5-min Apgar score <7* | 2 (50.0) | 2 (33.3) | 1.00 |
| Umbilical cord pH* | 7.35 (7.33-7.37) | 7.34 (7.30-7.38) | 1.00 |
| Umbilical cord BE* | −1.6 (−2.1-−0.1) | 0.0 (−2.2-1.3) | 1.00 |
| Intubation* | 3 (75.0) | 5 (83.3) | 1.00 |
| Thoracic drainage* | 3 (75.0) | 1 (16.7) | 1.00 |
| Octreotide therapy* | 3 (75.0) | 3 (50.0) | 0.571 |
| Steroid therapy* | 2 (50.0) | 2 (33.3) | 1.00 |
| Patient no. | Follow-up (m) | GA at TC (w) | GA at TAS (w) | GA at birth (w) | Location of FPE | Fetal hydrops | Histological CAM | Indication for birth | Birth weight (g) | Gender | UmA pH | UmA BE | Long-term outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 120 | 23 | 24 | 34 | Bilateral | Yes | Negative | NRFS | 2506 | Male | 7.29 | −2.7 | Typical development |
| 2 | 103 | 30 | 30 | 32 | Bilateral | No | Negative | HDP | 2004 | Female | 7.40 | 1.5 | Typical development |
| 3 | 86 | 24 | 25 | 37 | Bilateral | No | Positive | Full term | 2828 | Male | 7.30 | −6.1 | Typical development |
| 4 | 77 | 33 | 33 | 34 | Bilateral | No | Negative | NRFS | 2912 | Male | 7.42 | 1.8 | Typical development |
| 5 | 72 | 26 | 27 | 37 | Unilateral | No | Negative | Full term | 2880 | Male | 7.35 | 0.8 | Typical development |
| 6 | 72 | 28 | 30 | 37 | Unilateral | No | Negative | Full term | 3038 | Male | 7.31 | 1.0 | Typical development |
| 7 | 116 | 33 | 33 | 36 | Unilateral | No | Positive | Labor onset | 2568 | Male | 7.29 | −2.2 | Low IQ at age 6 |
| 8 | 93 | 21 | 25 | 37 | Bilateral | Yes | Negative | Full term | 2227 | Female | 7.35 | −2.0 | ADHD at age 7 |
| 9 | 90 | 30 | 30 | 33 | Bilateral | Yes | Negative | Labor onset | 2292 | Male | 7.35 | −1.1 | Developmental delay at age 7 (Language) |
| 10 | 80 | 31 | 31 | 38 | Bilateral | Yes | Positive | Full term | 2538 | Female | 7.43 | 3.1 | Low IQ at age 6 |
